Gel injection treatment of body parts

A substance injection device comprising:

• a transurethral apparatus including
• a) a first apparatus having
• i) a housing with a first channel, and an elongated tube extending from said first channel, and a handle configured for push-pull operation;
• and
• b) a second apparatus having
• i) a body with an elongated portion configured for a sliding fit in said first channel, and a hollow core needle extending from said body so as to be guided by said elongated tube, and a treatment substance input apparatus for forcing said treatment substance through said needle, and a ring wherein an operator can move said needle forward or backwards within said tube by an operator using said handle and said ring.

A method for treating a portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body part, said treatment substance including an active treatment substance, and an inactive substance;
• b) guiding said needle apparatus to target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance to said target tissue using said needle apparatus;
• wherein said treatment substance includes one or more substances selected from the group consisting of chemo-therapeutic agents and sclerosing agents, including ethanol, saline, acidic agents, epinephrine, biological agents, polymers, bioabsorbable polymers, proteins, conjugates plants, animal tissue derivates and byproducts and pharmaceutical drugs.

A method for treating a portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue using said needle apparatus;
• wherein the treatment substance includes a material selected from the group consisting of liquids, gases, solids, gels, viscous fluids, semi-liquid solutions, semi-solids, suspensions, colloids, micro spheres and conjugates.

A method for treating a portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to a target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue using said needle apparatus;
• wherein said treatment substance includes an element selected from the group consisting of chemo-therapeutic agents, sclerosing agents, ethanol, saline, acetic acid injectable agents, anesthetic agents, antibiotics, enzymes, biological agents, bioabsorbable polymers, biomaterials, conjugates, pharmaceutical drugs, genes, viruses, vasoconstricting agents, proteins, contrast agents, polymers, plant and animal tissue cell byproducts and derivatives, natural extracts/compounds and other biochemical agents.

A method for treating a portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body part, said treatment substance including an inactive binding substance and an active treatment substance.
• b) guiding said needle apparatus to a target tissue in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue;
• wherein said treatment substance is formulated with physical properties and specifications designed for treatment of specific body tissue and body organs selected from the group consisting of prostate, bladder, uterus, breast, vocal cords, gallbladder, pancreas, lungs, anus, colon, G.I. tract, kidney, liver and other body organs, body cavities and glands.

A method for treating a portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to a target tissue in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue;
• wherein said treatment substance is designed for treatment of a specific disease condition selected from the group consisting of BPH, enlarged prostate growth, prostatitis, prostate cancer, bladder tumors, breast tumors, cysts, breast cancer, pancreatic cancer, uterine fibroids, myomas, excessive uterine bleeding, uterine cyst cancer, lung tumor, hemorrhoids, gastric tissue growth, gastric cancer and tissue growth, tumors and disorder.

A method for treating a portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to a target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue;
• wherein said inserting includes passing said needle apparatus through a portion of said body selected from the group consisting of skin, interstitial material, rectum and urethra.

A method for treatment of a prostate comprising:

• a) inserting an injection needle apparatus in a prostate, said apparatus including at least one hollow core needle for delivery of a treatment substance into said prostate, said treatment substance including an inactive binding substance and an active treatment substance, and said injection needle apparatus including instrumentation selected from the group consisting of a biopsy needle guide, and a working channel of an endoscope;
• b) guiding said injection needle apparatus through a body passage selected from the group consisting of skin, urethra, rectum, perineum, and vesicle for treatment of a disease selected from the group consisting of BPH, enlarged prostate, and prostate cancer, said guiding using a method employing instrumentation selected from the group consisting of cystoscope, resectoscope, endoscope, and noninvasive image apparatus including transrectal ultrasound imaging apparatus, CT, MRI, and X-ray imaging apparatus;
• and
• c) injecting said treatment substance into said prostate through said injection apparatus;
• wherein said treatment substance includes elements selected from the group consisting of chemo-gels, including ethanol gel, saline gel, acetic acid gel, antibiotic gels, anesthetic gel, contrast agent gels, bioabsorbable polymer gel, epinephrine gel and tissue cell derivatives, chemo-therapeutic and other biochemical, polymer and biological gels.

A method for treating a localized portion of a prostate comprising:

• a) inserting an injection needle apparatus into a prostate, said apparatus including at least one hollow core needle for delivery of a treatment substance into said prostate, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said injection needle apparatus through a passage selected from the group consisting of a urethra, rectum, perineum, and vesicle, into said prostate for treatment of a disease selected from the group consisting of BPH, enlarged prostate and prostate cancer, using instrumentation selected from the group consisting of a cystoscope, resectoscope, endoscope, and non-invasive imaging apparatus selected from the group consisting of transrectal ultrasound imaging apparatus, CT, MRI, and x-ray apparatus;
• and
• c) injecting said treatment substance into said prostate through a said injection apparatus, selected from the group consisting of a biopsy needle guide, working channel of an endoscope, and ultrasound imaging probe;
• wherein said treatment substance includes elements selected from the group consisting of a chemo-gel formulation, sclerosing agent, anesthetic agent, antibiotic, enzyme, biological agent, bioabsorbable polymer, plant and animal tissue cell derivate and byproduct, vasoconstricting agent, biomaterial, conjugate, pharmaceutical agent, gene, virus, and other biochemical polymer and biological agents.

A formulation comprising:

• a treatment substance having a viscosity in the range of 1.0 to 10,000 cps for injection treatment of a prostate including an active treatment substance with at least one component selected from the group consisting of dehydrated ethyl alcohol (ethanol), saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents wherein said active treatment substance is 70-99% of said treatment substance;
• b) an inactive binding substance including at least one component selected from the group consisting of polymers, bioabsorbable polymers, hydroxyl propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said treatment substance.

A method of treating a prostate comprising:

• injecting into said prostate an injectable substance having a viscosity in the range of 1.0 to 10,000 eps for injection treatment of a prostate including an active treatment substance with at least one component selected from the group consisting of dehydrated ethyl alcohol (ethanol), saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents wherein said active treatment substance is 70-99% of said treatment substance;
• b) an inactive substance including at least one component selected from the group consisting of polymers and bioabsorbable polymers, hydroxyl propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said treatment substance.

A formulation comprising:

• a treatment substance having a viscosity in the range of 0.1 to 8000 cps for treatment of a prostrate disease selected from the group consisting of enlarged prostrate and BPH, said treatment substance including
• a) at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol (ethanol), saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of polymers, bioabsorbable polymers, hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said treatment substance.

A method of treating a prostate comprising:

• injecting into a prostate a treatment substance having a viscosity in the range of 0.1 to 8000 cps for treatment of a prostrate disease selected from the group consisting of enlarged prostrate and BPH, said treatment substance including
• a) at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol (ethanol), saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of polymers, bioabsorbable polymers, hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said substance.

A formulation comprising:

• a) a treatment substance having a viscosity in the range of 1 to 5000 cps for treatment of prostatitis, said treatment substance including at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol (ethanol), saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive substance including at least one component selected from the group consisting of polymers, bioabsorbable polymers, hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said substance.

A method of treating a prostate comprising:

• injecting into said prostate a treatment substance having a viscosity in the range of 1 to 5000 cps for treatment of prostatitis, said treatment substance including at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol (ethanol), saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of polymers, bioabsorbable polymers, hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said substance.

A formulation comprising:

• a treatment substance having a viscosity in the range of 500 to 10,000 cps for treatment of prostate cancer, said treatment substance including
• a) at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol/ethanol, saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of polymers, bioabsorbable polymers, hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) Epinephrine in the amount of 0 to 5.0% of said substance.

A method of treating a prostate comprising:

• injecting into said prostate a treatment substance having a viscosity in the range of 500 to 10,000 cps for treatment of prostate cancer, said treatment substance including
• a) at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol/ethanol, saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of polymers and bioabsorbable polymers, hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), HPEC, poly vinyl alcohol (PVA) and other rheollogy modification agents and materials;
• and
• c) epinephrine in the amount of 0 to 5.0% of said treatment substance.

A formulation comprising:

• a) a treatment substance having a viscosity in the range of 1 to 10,000 cps for treatment of a prostate, said treatment substance including at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol/ethanol, saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of the list of binding/gelling agents listed in FIG. 3;
• and
• c) epinephrine in the amount of 0 to 5.0% of said substance.

A method of treating a prostate comprising:

• a) injecting into said prostate a treatment substance having a viscosity in the range of 1 to 10,000 cps for treatment of a prostate, said treatment substance including at least one active treatment substance selected from the group consisting of dehydrated ethyl alcohol/ethanol, saline, epinephrine, hypertonic saline, acetic acid, phenol, and other sclerosing agents;
• b) an inactive binding substance including at least one component selected from the group consisting of the list of binding/gelling agents listed in FIG. 3;
• and
• c) epinephrine in the amount of 0 to 5.0% of said treatment substance.

A method for treating a localized portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to a target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue;
• wherein said inserting is accomplished using instrumentation selected from the group consisting of a working channel of a biopsy guide, endoscope and laparascope.

A method for treating a localized portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to a target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue;
• wherein said guiding includes use of instrumentation selected from the group consisting of an endoscope, laparascope, ultrasound imaging instrument and grid template.

A method for treating a localized portion of a body part comprising:

• a) inserting a needle apparatus in said body part, said apparatus including at least one hollow core needle for delivering a treatment substance into said body, said treatment substance including an inactive binding substance and an active treatment substance;
• b) guiding said needle apparatus to a target tissue in said body part in need of treatment including use of an imaging device;
• and
• c) injecting said treatment substance into said target tissue;
• wherein said guiding includes use of a non-invasive method selected from the group consisting of CT, MRI, ultrasound and X-ray method.

A treatment substance injection device comprising:

• a) a hollow core needle for passage of said treatment substance, and wherein said needle has an echogenic tip;
• b) a transrectal ultrasound probe including a needle guide attached for guiding said needle along an exterior of said probe;
• and
• c) needle tip protection apparatus for preventing said tip from contact with body tissue during installation of said probe in a body.

A treatment injection device comprising:

• a) a percutaneous device including
• i) a hollow core needle for passage of a treatment substance, said needle having an echogenic tip;
• and
• b) a propulsion apparatus for propelling said treatment substance through said needle.